journal article·2022-07Open access

The protein corona modulates the inflammation inhibition by cationic nanoparticles via cell-free DNA scavenging

Xingliang Liu, Huiyi Liang, Yanzi Yan, Jingjiao Wu, Massimo Bottini, Lixin Liu, Yongming Chen

Abstract

A central paradigm in nanomedicine is that when synthetic nanoparticles (NPs) enter the body, they are immediately cloaked by a corona of macromolecules (mostly proteins) that mediates the role of the physico-chemical properties in the NP biological functions (the "coronation paradigm"). In this work, we focused on the assessment of the "coronation paradigm" for cationic NPs (cNPs) used as rheumatoid arthritis (RA) drugs due to their ability to scavenge cell-free DNA (cfDNA). We fabricated series of cNPs uniformly coated with single or di-hydroxyl groups and different types of amino groups and showed that hydroxylated nanoparticles displayed a prolonged retention in inflamed joints and greater anti-inflammatory effect in collagen-induced arthritis (CIA) rats than the non-hydroxylated analogues. Especially, the cNPs with secondary amines and a di-hydroxyl shell showed the best performance among the tested cNPs. Proteomic analysis showed that the cNPs with a di-hydroxyl shell adsorbed less opsonin proteins than the cNPs carrying mono hydroxyl groups and non-hydroxylated ones, which may provide a mechanistic explanation for the different biodistribution profiles of cNPs. Thus, this study suggests that the protein corona mediates the effects of the surface chemistry on the fate and functions of cNPs as anti-RA drugs.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: RNA Interference and Gene Delivery · Rheumatoid Arthritis Research and Therapies · Immunotherapy and Immune Responses

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (42)

Show source-provided references
1. Nanomedicine for the treatment of rheumatoid arthritis10.1021/acs.molpharmaceut.0c00295 ↗
2. Engineering nanoparticles for targeting rheumatoid arthritis: past, present, and future trends10.1007/s12274-018-2071-3 ↗
3. Rheumatoid arthritis10.1016/S0140-6736(16)30173-8 ↗
4. Novel treatment strategies in rheumatoid arthritis10.1016/S0140-6736(17)31491-5 ↗
5. Utilization of nanoparticle technology in rheumatoid arthritis treatment, Biomed
6. Recent advances in nanomedicines for the treatment of rheumatoid arthritis10.1039/C7BM00254H ↗
7. Current trends in theranostics for rheumatoid arthritis10.1016/j.ejps.2020.105240 ↗
8. Cell-free DNA as a biomarker in autoimmune rheumatic diseases10.3389/fimmu.2019.00502 ↗
9. Increased concentrations of antibody-bound circulatory cell-free DNA in rheumatoid arthritis10.1373/clinchem.2006.084509 ↗
10. Microparticles as a source of extracellular DNA10.1007/s12026-010-8184-8 ↗
11. Membrane protected apoptotic trophoblast microparticles contain nucleic acids: relevance to preeclampsia10.2353/ajpath.2008.080414 ↗
12. Circulating cell free DNA: a marker to predict the therapeutic response for biological DMARDs in rheumatoid arthritis10.1111/1756-185X.12959 ↗
13. Identification of specific joint-inflammatogenic cell-free DNA molecules from synovial fluids of patients with rheumatoid arthritis10.3389/fimmu.2020.00662 ↗
14. Nucleic acid-binding polymers as anti-inflammatory agents10.1073/pnas.1105777108 ↗
15. HMGB proteins function as universal sentinels for nucleic-acid-mediated innate immune responses10.1038/nature08512 ↗
16. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide10.1038/nature06116 ↗
17. Induction of inflammatory and immune responses by HMGB1–nucleosome complexes: implications for the pathogenesis of SLE10.1084/jem.20081165 ↗
18. Toll-like receptor 9–dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE10.1038/ni1457 ↗
19. Decreased serum cell-free DNA levels in rheumatoid arthritis10.1007/s13317-015-0066-6 ↗
20. The long and short of circulating cell-free DNA and the ins and outs of molecular diagnostics10.1016/j.tig.2016.03.009 ↗
21. RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement10.1084/jem.20050630 ↗
22. Scavenging nucleic acid debris to combat autoimmunity and infectious disease10.1073/pnas.1607011113 ↗
23. Treatment of severe sepsis with nanoparticulate cell-free DNA scavengers10.1126/sciadv.aay7148 ↗
24. Topical nanoparticles interfering with the DNA-LL37 complex to alleviate psoriatic inflammation in mice and monkeys10.1126/sciadv.abb5274 ↗
25. Cationic nanoparticle as an inhibitor of cell-free DNA-induced inflammation10.1038/s41467-018-06603-5 ↗
26. Tuned cationic dendronized polymer as a molecular scavenger for rheumatoid arthritis treatment10.1002/ange.201813362 ↗
27. Cationic block copolymer nanoparticles with tunable DNA affinity for treating rheumatoid arthritis10.1002/adfm.202000391 ↗
28. Protein corona: a new approach for nanomedicine design10.2147/IJN.S129300 ↗
29. Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology10.1038/nnano.2013.181 ↗
30. Polyglycerol grafting shields nanoparticles from protein corona formation to avoid macrophage uptake10.1021/acsnano.0c02289 ↗
31. Linear polycations by ring-opening polymerization as non-viral gene delivery vectors10.1016/j.biomaterials.2013.03.083 ↗
32. PGMA-based star-like polycations with plentiful hydroxyl groups act as highly efficient miRNA delivery nanovectors for effective applications in heart diseases10.1002/adma.201602319 ↗
33. Effective delivery of hypertrophic miRNA inhibitor by cholesterol-containing nanocarriers for preventing pressure overload induced cardiac hypertrophy10.1002/advs.201900023 ↗
34. Regulation of macrophage recognition through the interplay of nanoparticle surface functionality and protein corona10.1021/acsnano.6b00053 ↗
35. Nanoparticle size is a critical physicochemical determinant of the human blood plasma corona: a comprehensive quantitative proteomic analysis10.1021/nn201950e ↗
36. Structure and biological role of vitronectin10.1146/annurev.cb.07.110191.001423 ↗
37. The impact of nanoparticle protein corona on cytotoxicity, immunotoxicity and target drug delivery10.2217/nnm.15.188 ↗
38. Human serum albumin nanoparticles modified with apolipoprotein A-I cross the blood-brain barrier and enter the rodent brain10.3109/1061186X.2010.513712 ↗
39. Albumin nanoparticles targeted with Apo E enter the CNS by transcytosis and are delivered to neurones10.1016/j.jconrel.2009.03.002 ↗
40. Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy10.1016/j.addr.2009.03.009 ↗
41. β2-Glycoprotein I is a major protein associated with very rapidly cleared liposomes in vivo, suggesting a significant role in the immune clearance of “non-self” particles10.1074/jbc.270.43.25845 ↗
42. Surface polyethylene glycol conformation influences the protein corona of polyethylene glycol-modified single-walled carbon nanotubes: potential implications on biological performance10.1021/nn400409h ↗